The Outbreak That Stress-Tested Veterinary Diagnostics at National Scale
The H5N1 highly pathogenic avian influenza outbreak that has been expanding across U.S. commercial poultry and dairy cattle since 2022 has functioned, among other things, as a stress test for the veterinary diagnostics infrastructure at a scale and urgency the industry has rarely faced. The virus’s detection in dairy cattle in 2024 — an entirely new host species in the United States — required the rapid deployment of cattle-specific surveillance and diagnostic protocols that did not previously exist at operational scale. The USDA APHIS response, coordinated through the National Veterinary Services Laboratories at Ames, Iowa, established the National Milk Testing Strategy in December 2024 as a mandatory surveillance programme specifically to detect H5N1 in dairy cattle through milk sample analysis — identifying the December 2025 Wisconsin dairy cattle H5N1 detection through exactly this mechanism. The programme represents a model for rapid deployment of novel diagnostic surveillance infrastructure in response to an active animal health emergency, and its architecture — mandatory sampling, laboratory network coordination, and real-time data integration through the USDA APHIS Wild Bird Avian Influenza Surveillance dashboard — has practical lessons for future zoonotic disease surveillance architecture.
From Reference Laboratory to Farm Gate: The Point-of-Care Diagnostic Revolution
One of the most operationally significant shifts in veterinary diagnostics that the HPAI crisis has accelerated is the push toward point-of-care testing that delivers actionable results in the field rather than requiring sample transport to centralised reference laboratories. The conventional model — in which a farm or clinic sends a sample to a reference laboratory and waits one to three days for a result — is adequate for routine surveillance but inadequate for outbreak response, where biosecurity decisions must be made within the window that early detection actually enables. IntelliSense’s Alveo Sense Poultry Avian Influenza Test addresses this gap directly: the palm-sized molecular analyser uses a patented direct electrical sensing of nucleic acid amplification to deliver H5N1 test results in approximately 45 minutes via a mobile app, at the point of need on the farm. For a producer discovering behavioural changes in a dairy herd, or a poultry farm manager noticing unexplained mortality, the difference between a 45-minute on-farm result and a 48-hour laboratory result is the difference between rapid biosecurity response and further uncontrolled spread. The development reflects a broader industry trend toward democratising diagnostic accuracy — bringing the sensitivity of molecular testing to settings where it was previously impractical.
Vetology’s Transparency Standard: Why Performance Metrics Matter in Clinical Settings
The veterinary diagnostics market’s AI integration story acquired a significant new chapter in early 2026 when Vetology became the first veterinary imaging AI company to publicly release its full performance metrics. In clinical veterinary practice, the adoption of AI diagnostic tools depends on a straightforward question: how accurate is it, and in what conditions? For a radiograph analysis tool that a veterinarian uses to identify pulmonary nodules, bone fractures, or organ abnormalities, the accuracy of the AI’s output directly affects patient care. Vetology’s decision to publish full performance data — sensitivity, specificity, and accuracy rates across diagnostic categories — before competitors created a transparency standard that the market had not previously established. The practical consequence: veterinary practices evaluating AI imaging tools can compare Vetology’s documented performance against the claims of other vendors, and in clinical settings where liability and patient outcomes are at stake, documented evidence of performance carries weight that marketing claims cannot replace.
Veterinary Diagnostic Imaging: A Stable Growth Category Getting More Capable
Diagnostic imaging — encompassing radiography, ultrasound, computed tomography, and video endoscopy systems — represents one of the most technically established segments of the veterinary diagnostics market, and one that is benefiting from parallel advances in AI-powered image analysis. Global veterinary imaging equipment is expected to reach $2.76 billion by 2030, growing at approximately 7% annually. The addition of AI interpretation layers to standard radiographic and ultrasound imaging is extending the clinical value of existing equipment: a digital radiograph that previously required a veterinary radiologist’s manual review now has AI-assisted pattern recognition capable of flagging abnormalities for veterinary attention, improving detection rates and reducing the time between image acquisition and clinical decision. For small practices without access to specialist veterinary radiologists — the majority of veterinary practices in most markets — AI-assisted imaging interpretation represents a genuine extension of diagnostic capability that was previously accessible only through referral to specialist centres.
USDA’s Surveillance Architecture: The Public Health Infrastructure Behind Animal Diagnostics
The veterinary diagnostics market’s most significant structural support is not a commercial technology platform but a public health infrastructure that most private sector participants depend on whether they recognise it explicitly or not. The USDA APHIS maintains what it describes as the strongest avian influenza surveillance programme in the world, monitoring for H5N1 in commercial and backyard birds, wild birds, and dairy cattle. The National Veterinary Services Laboratories at Ames, Iowa, serve as the confirmatory testing reference for positive detections across the entire national surveillance network. The CDC’s parallel surveillance systems track H5N1 activity in humans with animal exposures, providing the epidemiological link between animal health diagnostics and public health monitoring. This interagency infrastructure — USDA APHIS, NVSL, CDC, state animal health laboratories, and private reference laboratories working within a coordinated national network — represents the diagnostic ecosystem within which both public veterinary surveillance and private clinical diagnostics operate. Its capacity, its data-sharing architecture, and its speed of response to novel disease events directly shape the environment in which veterinary diagnostic companies develop, validate, and deploy their technologies.
What Veterinary Diagnostics Looks Like as the Infrastructure Matures
Constancy Researchers’ assessment: veterinary diagnostics in 2026 is a market whose trajectory has been materially shaped — and accelerated — by the H5N1 HPAI crisis, which has simultaneously demonstrated the importance of rapid point-of-care testing, driven federal investment in diagnostic infrastructure and surveillance capacity, and generated the kind of real-world, high-stakes validation environment that point-of-care diagnostic technologies need to prove their clinical value. The market’s structural growth, supported by rising pet ownership, growing livestock biosecurity requirements, and AI integration enabling new capability in both point-of-care and clinical imaging applications, is fundamentally sound. Vetology’s transparency move, IntelliSense’s 45-minute on-farm H5N1 test, and the USDA’s National Milk Testing Strategy together outline a diagnostics market that is being simultaneously pushed upmarket by AI capability and outward from the clinic by point-of-care technology — a combination that will define the sector’s competitive dynamics through the remainder of the decade.
Looking to navigate geopolitical risks and identify new industry opportunities?
Connect with Constancy Researchers for data-driven insights, geopolitical intelligence, and strategic consulting tailored to your business needs.
